LOS ANGELES - s4story -- Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.

Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.

Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.

RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection Utilizing Nvidia Blackwell Cluster with AI Healthcare Cloud Solutions.

On December 20th RENB announced its subsidiary Renovaro Cube has entered into a strategic collaboration with Nebul (www.nebul.com) a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases.

Nebul is a European NVIDIA NPN DGX Preferred Cloud Service Provider providing world-class supercomputing and GPU-accelerated business computing services, and a preferred cloud service provider in the NVIDIA Partner Network.

More on S For Story

• Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
• Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
• Houston Book Signing for "More Than My Sentence" Spotlights Life After Incarceration
• Impact & Influence September 2026: Joel Rodriguez Tirado on Relationships & True Partnership
• Impact & Influence August 2026: Joel Rodriguez Tirado on The Refocus Factor & Building Legacy

As part of this initiative, are plans for the RENB Renovaro Cube to deploy a dedicated NVIDIA SuperPOD powered by NVIDIA DGX B200™ systems, which feature the latest Blackwell GPU's, and apply NVIDIA Parabricks functionality to ensure optimal performance on the NVIDIA clusters. Each DGX B200 system delivers up to 72 petaFLOPS of training performance and 144 petaFLOPS of inference performance, providing the computational power necessary to integrate AI across medium-sized hospitals.

The RENB collaboration with Nebul aims to harness cutting-edge AI technologies and high-performance computing (HPC) built on the latest technology available from NVIDIA to transform diagnostic and therapeutic methodologies. This important step follows on finalization of a pilot project confirming our processing capabilities of liquid biopsy samples on NVIDIA's GPUs.

NVIDIA's newest Blackwell GPUs are revolutionizing the speed of processing genomic data at molecular level, for example from blood (cfDNA), which is crucial for timely diagnosis and treatment selection. By leveraging their unparalleled computational efficiency, Renovaro Cube will further develop non-invasive liquid biopsy technologies using cfDNA and 3rd-generation sequencing to analyze and interpret massive cfDNA datasets at high speed, providing healthcare providers with actionable insights faster than ever before.

Nebul, recognized for its expertise in developing and managing large-scale AI infrastructure, will oversee the operation of this Superpod cluster. This RENB collaboration extends to partnerships with institutions aiming to accelerate the adoption of AI in healthcare.

Arnold Juffer, Chief Executive Officer of Nebul, stated, "Supporting Renovaro in their mission to revolutionize healthcare through early detection and cancer diagnosis aligns well with Nebul's mission to supply cutting-edge AI technology in healthcare. The NVIDIA partnership, combined with deep expertise, true GDPR and legal compliance is developing into a powerful force in European AI advancement. This validates Nebul's approach into various European industries which value privacy, compliance and AI advancements. Nebul's relentless customer intimacy and support provides a strong differentiator for partners and clients."

More on S For Story

• Explosive New Book Warns Fate of the Nation Rides on 2026 Midterms
• Kenneth "KT" Thomas Releases New Book What If You Don't Quit? The F.L.I.G.H.T. Framework
• "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026
• Author Crystal Silva Establishes BreathWoven Book Store
• Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child

Strategic Restructuring and Leadership Transition

On October 16th RENB announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The RENB Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.

RENB new leadership led by David Weinstein, CEO, renowned senior Wall Street executive with 39 years in banking & analyst roles, recognized for developing dynamic growth strategies for a broad range of private and public companies with a focus on maximizing the value of innovative life science platforms.

RENB Revitalized Commitment to "Ambitious Innovation" Includes:

1) Strategic Asset Review & Pipeline Prioritization.

2) Commitment to Develop RENB RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships (Corporate & Academic).

3) Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement.

4) Financial Initiatives to Ensure the RENB Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline.

5) Synchronizing All Aspects of RRNB Business Units to Yield Maximum Benefits to Patients and Shareholders.

Company Name: Renovaro Inc. (Symbol: RENB)

Contact Person: David Weinstein, CEO

Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/

Email: ir@renovarobio.com

Phone: 732-780-5036

Home Country: United States

DISCLOSURE: www.corporateads.com